Skip to main content
Clinical Trials/IRCT20140818018842N33
IRCT20140818018842N33
Recruiting
Phase 1

Feasibility, safety, effectiveness and toxicity of Post-transplant Expanded, Activated Haploidentical Natural Killer Cells Infusion in Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients with Acute Myeloid Leukemia: A Pilot Study

Tehran University of Medical Sciences0 sites5 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
5
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \= 18 years old.
  • Patients must have a diagnosis of AML other than acute promyelocytic leukemia (APL) according to WHO criteria and should be a candidate for their first allogenic haploidentical HSCT.
  • All patients must have adequate organ function defined as:a.Renal Function: Age\-adjusted serum creatinine \= to 1\.5 x normal for age/gender OR creatinine clearance or GFR greater than or equal to 60 cc/min/1\.73m2b.Liver Function: Total bilirubin \= 1\.5 x normal for age, AND Alanine aminotransferase (ALT) is no more than 2 times the upper limit of normal and Aspartate transaminases (AST) is no more than 2 times the upper limit of normal.c.Cardiac Function: Normal ejection fraction documented by either echocardiogram or radionuclide MUGA evaluation OR Normal fractional shortening documented by echocardiogramd.Pulmonary Function: No dyspnea at rest, no oxygen requirement.
  • Karnofsky or Lansky performance score of greater than or equal to 50\.
  • Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation
  • At least two weeks since receipt of any biological therapy, systemic chemotherapy, and/or radiation therapy.

Exclusion Criteria

  • Pregnancy: Quantitative Serum B\-HCG must be negative in girls who are post\-menarchal
  • Breast feeding women are not eligible.
  • Active or uncontrolled infection
  • Patient declines participation

Outcomes

Primary Outcomes

Not specified

Similar Trials